The study analyzed that the chronic obstructive
pulmonary disease pipeline comprises 65 drug candidates
in different stages of development. Chronic obstructive pulmonary disease is a
broad term used for progression of various other diseases that affect the lungs
such as, emphysema, chronic bronchitis.
MorphoSys AG is using human
combinatorial antibody library (HuCAL) technology platform for the development
of their drug candidates in chronic obstructive pulmonary disease. The
technology is used for the in vitro generation of highly specific and fully
human antibodies.
Download Report
Sample at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis/report-sample
The research found that various
companies have collaborated for the development of chronic obstructive
pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co.,
Ltd. collaborated with AstraZeneca plc, had given the exclusive rights to
AstraZeneca plc for benralizumab in Asia.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=copd-therapeutics-pipeline-analysis
Some of the key players developing
drugs for the treatment of chronic obstructive pulmonary disease include
AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation and
others.
Chronic Obstructive Pulmonary
Disease Therapeutics Pipeline Analysis
By Phase
·
By
Route of Administration
·
By
Molecule Type
·
By
Company
